Primary Research Focus Areas

The PGJCCR organizes its scientific endeavors into several key thematic areas, focusing on the cancers that present the greatest clinical challenges and societal burden.

Gastrointestinal Cancers

The centre is world-renowned for its work on colorectal and esophageal cancers. Researchers focus on understanding the molecular subtyping of tumors to predict how patients will respond to specific treatments. This includes the development of the "Colorectal Cancer Subtyping Consortium" (CRCSC) framework, which is used globally to classify bowel cancer based on gene expression.

Blood Cancers (Hematology)

The hematology research group focuses on myeloid and lymphoid malignancies, including Acute Myeloid Leukemia (AML) and Myeloma. The objective is to identify novel therapeutic targets and understand the mechanisms of drug resistance in blood-borne cancers.

Prostate and Urological Cancers

The centre leads significant international trials and biological studies in prostate cancer. Research focuses on advanced radiotherapy techniques, the biology of metastatic disease, and the identification of biomarkers that can distinguish between indolent and aggressive disease forms.

Advanced Radiotherapy and Radiation Biology

Leveraging high-end physics and biological sciences, this theme explores how radiation interacts with cancer cells. The centre works on optimizing delivery systems and combining radiotherapy with immunotherapy or targeted molecular agents to enhance efficacy while reducing side effects for the patient.

Core Facilities and Services

The PGJCCR provides an extensive range of technological services and infrastructure that support both internal academic projects and external collaborations with pharmaceutical and MedTech companies.

The Northern Ireland Biobank (NIB)

A cornerstone of the centreâ??s infrastructure, the NIB provides high-quality, well-annotated human biospecimens (tissue, blood, and fluids) for research. This service is critical for the validation of biomarkers and the development of new diagnostic tools. The biobank operates under strict ethical and regulatory frameworks, ensuring data integrity for clinical research.

Genomics Core Technology Unit

The Genomics Core offers state-of-the-art sequencing and analysis services. This includes: * Next-Generation Sequencing (NGS) for whole genome, exome, and RNA sequencing. * Single-cell transcriptomics to understand tumor heterogeneity. * Specialist bioinformatics support for large-scale genomic data interpretation.

Digital Pathology and Image Analysis

The centre is a leader in digital pathology, utilizing high-resolution scanning and Artificial Intelligence (AI) algorithms to analyze tissue sections. These services allow for the objective quantification of biomarkers and the assessment of the tumor microenvironment, which are essential for precision medicine trials.

Medicinal Chemistry and Drug Discovery

This unit works on translating biological findings into chemical entities. Services include: * Target identification and validation. * Small molecule synthesis and optimization. * Pharmacokinetic and pharmacodynamic profiling of lead compounds.

Bioinformatics and Data Science

The PGJCCR houses a dedicated team of bioinformaticians who provide computational modeling, pathway analysis, and integrative data services. This allows researchers to bridge the gap between raw experimental data and actionable clinical insights.

Clinical Trials and Translational Impact

The PGJCCR is inextricably linked with the Northern Ireland Cancer Trials Network (NICTN) and the Northern Ireland Clinical Trials Unit (NICTU). This integration allows the centre to offer:

• Early Phase Clinical Trials: Testing novel compounds and therapeutic strategies in humans for the first time.
• Biomarker-Driven Trials: Designing protocols where patient treatment is dictated by the specific molecular profile of their tumor.
• Clinical Trial Coordination: Providing the regulatory and operational framework necessary to conduct multi-center oncology trials.

Industry Engagement and MedTech Partnerships

The PGJCCR operates as a key partner for the MedTech and Bio-Pharmaceutical industry. It facilitates "Knowledge Transfer Partnerships" (KTPs) and collaborative research agreements.

Services for Industry Partners:

1. Target Validation: Utilizing the centreâ??s advanced laboratory models to verify the biological relevance of a drug target.
2. Companion Diagnostic Development: Assisting companies in developing tests that identify which patients will benefit from a specific drug.
3. Pre-clinical Testing: Providing in vitro and in vivo models, including patient-derived xenografts (PDX), to test the efficacy of new therapeutic candidates.
4. Access to Expert Consultancy: Providing industry with access to world-leading oncologists and molecular biologists for strategic development advice.

Education and Training

As part of Queen's University Belfast, the PGJCCR offers advanced educational programs that produce the next generation of cancer researchers and clinical oncologists. This includes: * MSc in Cancer Medicine: A program focusing on the modern clinical and laboratory aspects of oncology. * PhD and MD Programs: Intensive research degrees focused on original contributions to cancer science. * Professional Development: Specialized training in clinical trial management, bioinformatics, and laboratory techniques for industry professionals.

By combining high-level academic research with robust clinical infrastructure and industrial collaboration, the Patrick G Johnston Centre for Cancer Research serves as a vital engine for innovation in the United Kingdomâ??s medical and health sector.